Dr Mike Bromley

MFIG is delighted to announce the appointments of Dr Mike Bromley as Director and Prof David Denning as Deputy Director of MFIG.

As a former co-director of MFIG, Mike is an internationally recognised leader in the study of drug resistance and drug discovery in human fungal pathogens. After his PhD, he started his research career at the antifungal drug discovery company F2G Ltd. During his 7 years at the company, Mike led the novel target discovery efforts and contributed to the identification of the mechanism of action of the antifungal drug series Olorofim. Since his appointment at Manchester, Mike has led large scale collaborative efforts to identify novel antifungals and is currently working on the development of two novel classes of antifungal drug. Mike also leads the Wellcome funded A. fumigatus genome wide knockout initiative (COFUN) and has published extensively on novel mechanisms of antifungal drug resistance. He has successfully launched a number of commercial companies including Genon Laboratories Ltd, Syngenics Ltd and PiQ Laboratories Ltd.

Prof David Denning

David is an infectious diseases clinician with expertise in fungal diseases and founding Director of the National Aspergillosis Centre in Manchester (2009-2020). He has successfully lead many major international collaborative science, diagnostic and treatment projects and clinical guidelines, with subsequent publication in Nature, the New England Journal of Medicine and the Lancet. In addition to his university roles, he is Chief Executive of the Global Action Fund for Fungal Infections (www.GAFFI.org). He co-chairs the alternate year Advances Against Aspergillosis and Mucormycosis meetings. He is a member of the SEARO Task Force on AMR. He has published extensively, primarily on Aspergillus and aspergillosis and is the founder of 2 University spinout biotechnology companies – F2G Ltd and Myconostica Ltd.

Mike says

“Over a billion people are afflicted with a fungal disease at any given moment and each year over 1.5 million people die. Multidrug-resistant fungi are currently sweeping the world causing significant impacts on health outcomes. We stand at a pivotal point in our battle against antifungal drug resistance. With a number of promising novel antifungals close to regulatory approval, it is critical that we understand how best to use these agents to reduce the emergence of resistance and so prolong their effectiveness. Working closely with our teams in the National Aspergillosis Center, The Mycology Reference Centre and collaborators across the globe our objectives are to improve the accuracy of infection diagnosis, understand the drivers of antifungal resistance, develop strategies to tackle the emergence of resistance and translate these solutions at pace with our clinical partners.”

Related